Commentary|Podcasts|January 4, 2024

Reshaping Pharmacovigilance in the Age of AI

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, joins Miranda Schmalfuhs to discuss:

  • His career background and current role
  • Indegene's new study Reshaping Pharmacovigilance in the Age of AI
  • What's holding the industry back from artificial intelligence/machine learning adoption
  • How to keep/utilize existing employees when adopting AI/ML technologies
  • Current automations trends
  • Where the industry is headed

About the speaker

Sameer Lal holds a bachelor of science degree and a bachelor of science (technology) degree, both from University of Mumbai and master of management studies degree from the Narsee Monjee Institute of Management Studies, Mumbai. He has 25+ years of experience in pharmaceutical industry and technology-led healthcare solutions provider sector. Prior to joining Indegene, Inc., he was associated with GlaxoSmithKline Pharmaceuticals Limited, Ranbaxy Laboratories Limited and Sudler & Hennessey Private Limited.

About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.